Stereoselective Conjugation of Oxazepam by Human UDP-Glucuronosyltransferases (UGTs): S-Oxazepam Is Glucuronidated by UGT2B15, While R-Oxazepam Is Glucuronidated by UGT2B7 and UGT1A9
- 1 November 2002
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 30 (11) , 1257-1265
- https://doi.org/10.1124/dmd.30.11.1257
Abstract
(R,S)-Oxazepam is a 1,4-benzodiazepine anxiolytic drug that is metabolized primarily by hepatic glucuronidation. In previous studies, S-oxazepam (but not R-oxazepam) was shown to be polymorphically glucuronidated in humans. The aim of the present study was to identify UDP-glucuronosyltransferase (UGT) isoforms mediating R- and S-oxazepam glucuronidation in human liver, with the long term objective of elucidating the molecular genetic basis for this drug metabolism polymorphism. All available recombinant UGT isoforms were screened for R- and S-oxazepam glucuronidation activities. Enzyme kinetic parameters were then determined in representative human liver microsomes (HLMs) and in UGTs that showed significant activity. Of 12 different UGTs evaluated, only UGT2B15 showed significant S-oxazepam glucuronidation. Furthermore, the apparent Km for UGT2B15 (29–35 μM) was similar to values determined for HLMs (43–60 μM). In contrast, R-oxazepam was glucuronidated by UGT1A9 and UGT2B7. Although apparent Km values for HLMs (256–303 μM) were most similar to UGT2B7 (333 μM) rather than UGT1A9 (12 μM), intrinsic clearance values for UGT1A9 were 10 times higher than for UGT2B7. A common genetic variation results in aspartate (UGT2B15*1) or tyrosine (UGT2B15*2) at position 85 of the UGT2B15 protein. Microsomes from human embryonic kidney (HEK)-293 cells overexpressing UGT2B15*1 showed 5 times higherS-oxazepam glucuronidation activity than did UGT2B15*2 microsomes. Similar results were obtained for other substrates, including eugenol, naringenin, 4-methylumbelliferone, and androstane-3α-diol. In conclusion, S-oxazepam is stereoselectively glucuronidated by UGT2B15, whereasR-oxazepam is glucuronidated by multiple UGT isoforms. Allelic variation associated with the UGT2B15 gene may explain polymorphic S-oxazepam glucuronidation in humans.Keywords
This publication has 18 references indexed in Scilit:
- Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 genePharmacogenetics, 2000
- Characterization of UDP-glucuronosyltransferases active on steroid hormonesThe Journal of Steroid Biochemistry and Molecular Biology, 1999
- Isolation and characterization of UGT2B15(Y85): a UDP glucuronosyltransferase encoded by a polymorphic genePharmacogenetics, 1997
- Biochemical Basis for Deficient Paracetamol Glucuronidation in Cats: an Interspecies Comparison of Enzyme Constraint in Liver MicrosomesJournal of Pharmacy and Pharmacology, 1997
- Molecular basis for deficient acetaminophen glucuronidation in catsBiochemical Pharmacology, 1997
- Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepamPharmacogenetics, 1995
- (S )Oxazepam glucuronidation is inhibited by Ketoprofen and other substrates of UGT2B7Pharmacogenetics, 1995
- Separation, isolation and identification of optical isomers of 1,4-benzodiazepine glucuronides from biological fluids by reversed-phase high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1984
- Clinical Pharmacokinetics of Oxazepam and LorazepamClinical Pharmacokinetics, 1981
- Biochemical identification of the site of action of benzodiazepines in human brain by 3H-diazepam bindingLife Sciences, 1978